Coverage
-
October 17, 2012
Pfizer Inc. told a New York federal judge Tuesday that health care benefit funds bringing a putative class action over its allegedly illegal copayment subsidies for prescription drugs have failed to properly allege that the copay coupon program hurt their business, and that their antitrust and racketeering claims must be axed.
1 other articles on this case.
View all »